Biocon Ltd receives U.S. FDA approval for Pebrilzo, a Perjeta biosimilar for HER2-positive breast cancer
- Approved for specified treatment regimens in HER2-positive metastatic and early breast cancer.
- Biocon’s oncology portfolio now includes five U.S.-approved cancer biosimilars.
- Under a settlement and licence agreement with Genentech, the earliest U.S. launch is expected in Q3 2028.
